Literature DB >> 2440140

Cyclosporin-A induced heart failure after orthotopic heart transplantation.

A Laczkovics, M Havel, H Teufelsbauer, R Horvath, W Schreiner, E Wolner.   

Abstract

Two patients suffering from dilated Cardiomyopathy (CMP) had to undergo orthotopic heart transplantation (HTX). In both cases, the postoperative period was without any complications. The immunosuppression consisted of Cyclosporin-A and Azathioprine including a one week prophylactic treatment with Antithymocyte Globuline (ATG). Four months postoperatively, they developed clinical signs of heart failure. The endomyocardial biopsies showed rejection at stage I according to Billingham's grading plus a fine interstitial fibrosis. Therefore, the Cyclosporin treatment was suspended and replaced by conventional immunosuppression consisting of Prednisolone and Azathioprine. Acute heart failure was managed by catecholamines in combination with aggressive diuretic therapy. After three weeks, both patients recovered. 12 weeks later, one died because of an acute rejection episode. The other is in good condition, with conventional immunosuppression at the present time. A vascular process caused by Cyclosporin-A as the pathogenic mechanism is considered. The absence of rejection signs in the biopsies as well as the remarkable improvement of heart failure after withdrawal of Cyclosporin-A support this possibility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440140     DOI: 10.1055/s-2007-1020202

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  2 in total

1.  Knockdown of dishevelled-1 attenuates cyclosporine A-induced apoptosis in H9c2 cardiomyoblast cells.

Authors:  Yejing Zhu; Jinyu Chi; Yue Liu; Yihua Sun; Yu Fu; Xiaohui Zhang; Xueliang Ding; Xinhua Yin; Dechao Zhao
Journal:  Mol Cell Biochem       Date:  2012-11-18       Impact factor: 3.396

2.  Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production.

Authors:  M Shenoy; B MacPherson; P Christadoss
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.